Publication—Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

Written By Vikki Christian

Taylor MH, Naing A, Powderly J, et al. Journal for ImmunoTherapy of Cancer. November 21, 2024

Vikki Christian
Previous

Oral Presentation—IO-202, A Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
Next

Poster presented—Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort